<DOC>
	<DOC>NCT00518583</DOC>
	<brief_summary>The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.</brief_summary>
	<brief_title>Phase II Study in Patients With Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Dx of clinical T1cT3, N01, M0 breast cancer Interval between diagnosis and consent of &lt; 62 days Life expectancy of 10 years LVEF by MUGA &gt;= lower limit of normal for the testing facility Negative serum pregnancy test Adequate bone marrow, renal, liver function Negative bone scan HRT discontinued before study entry Adequate contraceptive methods Male breast cancer Less than 21 years of age Ulceration, infiltration of the skin, complete fixation or severe skin edema N3 disease in which nodes are matted and fixed Suspicious palpable supraclavicular nodes CT evidence of malignant internal mammary nodes Pregnancy or breast feeding at time of study entry Prior therapy for breast cancer Prior anthracycline for any malignancy Prior breast malignancy of the contralateral breast Prior nonbreast malignancy within 5 years Nonmalignant disease that would preclude follow up MI within 6 months, NYHA Class II or greater heart failure Psychiatric disorders or conditions that would preclude provision of informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Over-expressing Her2-neu</keyword>
</DOC>